Gene network profiling in muscle-invasive bladder cancer: A systematic review and meta-analysis.
Bladder cancer
Gene expression
Muscle-invasive bladder cancer
Urothelial cancer
Journal
Urologic oncology
ISSN: 1873-2496
Titre abrégé: Urol Oncol
Pays: United States
ID NLM: 9805460
Informations de publication
Date de publication:
05 2022
05 2022
Historique:
received:
12
09
2021
revised:
17
10
2021
accepted:
02
11
2021
pubmed:
19
1
2022
medline:
11
5
2022
entrez:
18
1
2022
Statut:
ppublish
Résumé
Determining meta-analysis of transcriptional profiling of muscle-invasive bladder cancer (MIBC) through Gene Expression Omnibus (GEO) datasets has not been investigated. This study aims to define gene expression profiles in MIBC and to identify potential candidate genes and pathways. To review and evaluate gene expression studies in MIBC through publicly available RNA sequencing (RNA-Seq) and microarray data in order to identify potential prognostic and therapeutic targets for MIBC. A systematic literature search of the Ovid MEDLINE, PubMed, and Wiley Cochrane Central Register of Controlled Trials databases was performed using the terms "gene," "gene expression," and "bladder cancer" January 1, 1990 through March 2021 focused on populations with MIBC. In the final analysis, GEO datasets were included. Fixed effect model was employed in the meta-analysis. Gene networking connections and gene-set functional analyses of the identified genes as differentially expressed in MIBC were performed using ImaGEO and GeneMANIA software. A heatmap for the upregulated and downregulated genes was generated along with the correlated pathways. A total of 9 genes were reported in this analysis. Six genes were reported as upregulated (ProTα, SPINT1, UBE2E1, RAB25, KPNB1, HDAC1) and 3 genes as downregulated (NUP188, IPO13, NUP124). Genes were found to be involved in "ubiquitin mediated proteolysis," "protein processing in endoplasmic reticulum," "transcriptional misregulation in cancer," and "RNA transport" pathways.
Sections du résumé
BACKGROUND
Determining meta-analysis of transcriptional profiling of muscle-invasive bladder cancer (MIBC) through Gene Expression Omnibus (GEO) datasets has not been investigated. This study aims to define gene expression profiles in MIBC and to identify potential candidate genes and pathways.
OBJECTIVES
To review and evaluate gene expression studies in MIBC through publicly available RNA sequencing (RNA-Seq) and microarray data in order to identify potential prognostic and therapeutic targets for MIBC.
METHODS
A systematic literature search of the Ovid MEDLINE, PubMed, and Wiley Cochrane Central Register of Controlled Trials databases was performed using the terms "gene," "gene expression," and "bladder cancer" January 1, 1990 through March 2021 focused on populations with MIBC.
RESULTS
In the final analysis, GEO datasets were included. Fixed effect model was employed in the meta-analysis. Gene networking connections and gene-set functional analyses of the identified genes as differentially expressed in MIBC were performed using ImaGEO and GeneMANIA software. A heatmap for the upregulated and downregulated genes was generated along with the correlated pathways.
CONCLUSION
A total of 9 genes were reported in this analysis. Six genes were reported as upregulated (ProTα, SPINT1, UBE2E1, RAB25, KPNB1, HDAC1) and 3 genes as downregulated (NUP188, IPO13, NUP124). Genes were found to be involved in "ubiquitin mediated proteolysis," "protein processing in endoplasmic reticulum," "transcriptional misregulation in cancer," and "RNA transport" pathways.
Identifiants
pubmed: 35039218
pii: S1078-1439(21)00484-1
doi: 10.1016/j.urolonc.2021.11.003
pmc: PMC10123538
mid: NIHMS1891008
pii:
doi:
Substances chimiques
Rab25 protein, human
0
rab GTP-Binding Proteins
EC 3.6.5.2
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
197.e11-197.e23Subventions
Organisme : NIDDK NIH HHS
ID : TL1 DK132770
Pays : United States
Informations de copyright
Copyright © 2021 Elsevier Inc. All rights reserved.
Références
Cold Spring Harb Perspect Biol. 2014 Apr 01;6(4):a018713
pubmed: 24691964
J Clin Med. 2016 Jan 26;5(2):
pubmed: 26821054
BMC Med Res Methodol. 2014 Apr 01;14:45
pubmed: 24690082
PLoS One. 2013 Apr 04;8(4):e61088
pubmed: 23593398
Oral Oncol. 2013 Nov;49(11):1043-50
pubmed: 24035721
Yale J Biol Med. 1996 Jan-Feb;69(1):1-8
pubmed: 9041684
Traffic. 2014 Jul;15(7):727-48
pubmed: 24766099
Cancer Res. 2003 Mar 1;63(5):1101-5
pubmed: 12615728
Int J Mol Sci. 2013 May 24;14(6):11061-71
pubmed: 23708104
Proc Natl Acad Sci U S A. 2017 Aug 29;114(35):E7301-E7310
pubmed: 28811376
Oncogene. 2018 May;37(22):2936-2952
pubmed: 29520102
Clin Cancer Res. 2002 Apr;8(4):1101-7
pubmed: 11948120
J Physiol. 2004 Jan 1;554(Pt 1):22-30
pubmed: 14678487
J Korean Med Sci. 2014 Mar;29(3):351-6
pubmed: 24616583
iScience. 2020 Jun 26;23(6):101201
pubmed: 32521509
J Cell Biol. 2014 May 12;205(3):301-12
pubmed: 24821838
Brief Bioinform. 2010 Mar;11(2):253-64
pubmed: 19965979
Oncol Lett. 2016 Dec;12(6):4485-4492
pubmed: 28101210
Int J Biochem Cell Biol. 1999 Nov;31(11):1243-8
pubmed: 10605816
Int J Biochem Cell Biol. 2014 Feb;47:113-7
pubmed: 24361302
Ann Surg. 2005 Jan;241(1):16-26
pubmed: 15621987
Bladder Cancer. 2018 Apr 26;4(2):215-226
pubmed: 29732392
Int J Mol Sci. 2019 May 27;20(10):
pubmed: 31137849
PLoS One. 2011 May 05;6(5):e19213
pubmed: 21573209
Oncogene. 2007 Aug 13;26(37):5420-32
pubmed: 17694083
Urology. 2009 Jan;73(1):188-92
pubmed: 18692879
Oncogene. 2017 Mar 23;36(12):1707-1720
pubmed: 27694895
Cancer Cell. 2014 Feb 10;25(2):152-65
pubmed: 24525232
Sci Rep. 2021 Feb 19;11(1):4233
pubmed: 33608588
Ecancermedicalscience. 2016 Nov 24;10:ed61
pubmed: 28101141
Cancer Sci. 2013 Jul;104(7):871-9
pubmed: 23551833
Front Oncol. 2021 Jan 08;10:613869
pubmed: 33489923
Oncotarget. 2016 Oct 4;7(40):65403-65417
pubmed: 27557492
J Biol Chem. 2017 Feb 17;292(7):2893-2902
pubmed: 28073915
Neuropathology. 2013 Apr;33(2):149-61
pubmed: 22816789
Methods Mol Biol. 2016;1418:93-110
pubmed: 27008011
J Pharm Bioallied Sci. 2012 Jan;4(1):21-6
pubmed: 22368395
J Cell Mol Med. 2008 Oct;12(5B):1863-71
pubmed: 18657223
J Biol Chem. 2019 Mar 1;294(9):3207-3218
pubmed: 30593508
Bioinformatics. 2019 Mar 1;35(5):880-882
pubmed: 30137226
Am J Obstet Gynecol. 2006 Aug;195(2):373-88
pubmed: 16890548
Clin Epigenetics. 2018 Jul 31;10(1):100
pubmed: 30064501
Expert Rev Anticancer Ther. 2010 Dec;10(12):1945-54
pubmed: 21110760
Int J Mol Sci. 2019 Mar 14;20(6):
pubmed: 30875794
Histochem Cell Biol. 2018 Jun;149(6):635-644
pubmed: 29532159
Exp Mol Med. 2018 Jan 26;50(1):e435
pubmed: 29371698
Oncogene. 2019 Jun;38(24):4700-4714
pubmed: 30742095
Biomed Res Int. 2015;2015:168682
pubmed: 25866762
Med Sci Monit. 2020 Mar 09;26:e921087
pubmed: 32147666
Nature. 2004 Dec 16;432(7019):815-6
pubmed: 15602540
J Hematol Oncol. 2016 Nov 17;9(1):125
pubmed: 27855695
Curr Biol. 2002 Aug 20;12(16):1442-7
pubmed: 12194828
PLoS One. 2013;8(3):e57542
pubmed: 23469203
Oncotarget. 2016 Dec 6;7(49):81463-81473
pubmed: 27806337
Ann Acad Med Stetin. 2000;46:217-29
pubmed: 11712306
Biochem Biophys Res Commun. 2001 Nov 23;289(1):205-11
pubmed: 11708800
Cancer Metastasis Rev. 2011 Jun;30(2):239-51
pubmed: 21298575
Ann Appl Stat. 2014 Dec;8(4):2150-2174
pubmed: 25541588
Nucleic Acids Res. 2009 Jan;37(1):1-13
pubmed: 19033363
BMJ. 2009 Jul 21;339:b2535
pubmed: 19622551
Mol Cancer. 2015 Feb 15;14:42
pubmed: 25743594
Cell Chem Biol. 2018 Sep 20;25(9):1056-1058
pubmed: 30241601
Syst Rev. 2016 Dec 5;5(1):210
pubmed: 27919275
Hum Genomics. 2010 Feb;4(3):202-6
pubmed: 20368141
Cancer Res. 2013 Apr 15;73(8):2659-70
pubmed: 23447577
Biochem Biophys Res Commun. 2008 Sep 26;374(3):570-5
pubmed: 18655774
Carcinogenesis. 2013 Oct;34(10):2401-8
pubmed: 23722651
PeerJ. 2017 Feb 15;5:e3003
pubmed: 28229027
EBioMedicine. 2016 Oct;12:105-117
pubmed: 27612592
Scand J Clin Lab Invest. 2017 Oct;77(6):437-441
pubmed: 28609200
Nature. 2014 Nov 27;515(7528):558-62
pubmed: 25428503
CA Cancer J Clin. 2015 Mar;65(2):87-108
pubmed: 25651787
Cancer Sci. 2019 Apr;110(4):1208-1219
pubmed: 30719818
Nucleic Acids Res. 2000 Jan 1;28(1):27-30
pubmed: 10592173
Bioinformatics. 2005 Nov 15;21(22):4155-61
pubmed: 16118262
Genome Biol. 2007;8(9):R183
pubmed: 17784955
Int J Cancer. 2011 Jun 1;128(11):2613-24
pubmed: 20715109
Expert Rev Anticancer Ther. 2012 Jul;12(7):941-50
pubmed: 22845409
Bioinformatics. 2003 Jan 22;19(2):185-93
pubmed: 12538238
Oncol Rep. 2021 Jan;45(1):191-201
pubmed: 33200223
Cancer Sci. 2021 Jun;112(6):2199-2209
pubmed: 33686769
Lung Cancer. 2004 Nov;46(2):171-8
pubmed: 15474665
Sci Rep. 2020 Nov 26;10(1):20670
pubmed: 33244139
Nat Rev Cancer. 2015 Jan;15(1):25-41
pubmed: 25533674
J Biol Chem. 2013 Jun 7;288(23):16975-16985
pubmed: 23603909
PeerJ. 2016 Jan 21;4:e1621
pubmed: 26844019
Cells. 2019 Jan 21;8(1):
pubmed: 30669574
Bioinformatics. 2005 May 15;21(10):2417-23
pubmed: 15731210
Oncol Rep. 2016 Jul;36(1):441-7
pubmed: 27221765
Genome Biol. 2008;9 Suppl 1:S4
pubmed: 18613948
Mol Cancer Ther. 2017 Dec;16(12):2656-2667
pubmed: 28878027
Oncotarget. 2017 Jul 25;8(30):49783-49795
pubmed: 28572537
Cancer Epidemiol Biomarkers Prev. 2006 Feb;15(2):217-27
pubmed: 16492908